At Sapphire Clinics, one of our founding principles is to ensure that we are adding to the research base that is available on medical cannabis, one of the key barriers to NHS access.
We are happy to share 4 new condition-specific research publications with you from the UK Medical Cannabis Registry that our researchers at Sapphire have been working hard on.
Those enrolled on the UK Medical Cannabis Registry have helped us with the following pieces of research: Post-Traumatic Stress Disorder, Inflammatory Bowel Disease, Depression and Children with Treatment-Resistant Epilepsy.
The aim of the UK Medical Cannabis Registry is to expand our understanding of medical cannabis in the UK by collecting and analysing clinical data. The Registry ensures that medical cannabis prescribing is evaluated in a responsible way, capturing essential data including prescribed formulations, adverse events, and patient-reported outcome measures. Data is collected from patients who consent via the Curaleaf Access Scheme. You can learn more about the Curaleaf Access Scheme here.
We would like to extend thanks to all who are signed up to the Curaleaf Access Scheme without whom this research would not be possible.
